Stealth-mode biotech Treeline Biosciences has revealed its first cancer drug candidates entering clinical trials and announced an additional $200 million in funding, accumulating over $1.1 billion to date. The company is pursuing a diversified, well-financed pipeline addressing oncology targets such as a BCL6 protein degrader for lymphoma and a broad-spectrum KRAS mutant inhibitor for solid tumors. Treeline also licensed a therapy targeting EZH2 from Jiangsu Hengrui Pharmaceuticals, testing in T-cell lymphoma. Its model of multiple complementary programs aims to break industry milestone-to-milestone norms.